UNSPSC 51386014: Sulprosal

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85LCU5151G. European Medicines Agency schedules Sulprosal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10759MIG. Sulprosal generally arises in the molecular formula C10H12O6S. The term SULPROSAL is an International Non-Proprietary Name or INN. SULPROSAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

As of Q4 2014, SULPROSAL remains the US FDA Preferred Term for this commodity. Sulprosal bears US NLM identifiers UMLS ID C1883217 and NCI Concept Code C66575. SMILES: C1=CC=C(C(=C1)C(=O)OCCCS(=O)(=O)O)O.

UNSPSC 51386014 Sulprosal is a Commodity code that in practice captures state and local procurement of pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter medications distributed through community health systems, cooperative purchasing alliances, and state health agencies. The code encompasses both direct purchase of named pharmaceuticals and framework agreements that establish pricing and supply relationships with authorized wholesalers and manufacturers. Issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing organizations that procure on behalf of multiple participating jurisdictions. Recent solicitations show procurement offices using competitive bidding (IFB), Request for Proposal (RFP), and Request for Information (RFI) mechanisms to establish supply contracts with specific performance requirements including cGMP certification, Drug Supply Chain Security Act compliance, insurance coverage thresholds, and EDI capability.

Geographic activity centers on Florida and the upper Midwest, with Texas health agencies conducting early-stage market research. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026 and evaluated 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on administrative compliance and EDI capability. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor information about direct-to-manufacturer prescription programs and pharmacy benefit management alternatives, signaling potential future formal procurement activity in that state.